With FDA de­ci­sion one month away, Proven­tion part­ners with Sanofi on US mar­ket­ing for type 1 di­a­betes drug

Though its FDA de­ci­sion is one month away, Proven­tion Bio has al­ready be­gun its com­mer­cial ef­forts for its type 1 di­a­betes drug — and it’s now work­ing with Sanofi.

Sanofi has signed on as Proven­tion’s po­ten­tial com­mer­cial part­ner in the US if teplizum­ab, Proven­tion’s an­ti­body treat­ment for de­lay­ing the on­set of symp­to­matic type 1 di­a­betes, gets ap­proved in No­vem­ber. Sanofi will in­vest $35 mil­lion up­on ap­proval at a 40% pre­mi­um per share.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER